AN2 Therapeutics (ANTX) Cash & Equivalents (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Cash & Equivalents data on file, last reported at $53.5 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 167.64% year-over-year to $53.5 million in Q1 2026; TTM through Mar 2026 was $53.5 million, a 167.64% increase from a year earlier, with the FY2025 full-year figure at $19.9 million, down 6.6% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $53.5 million, up from $19.9 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ANTX reached as high as $82.5 million in Q1 2022 and fell as low as $15.6 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $31.2 million across 5 years, with a median of $26.8 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 67.63% in 2023 and jumped 167.64% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $27.2 million in 2022, then slumped by 42.51% to $15.6 million in 2023, then jumped by 36.45% to $21.4 million in 2024, then decreased by 6.6% to $19.9 million in 2025, then surged by 168.23% to $53.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $53.5 million in Q1 2026, $19.9 million in Q4 2025, and $18.0 million in Q3 2025.